Accumulating evidence suggests androgen receptor splice variant 7 (AR-V7) may be associated with the prognosis of castration-resistant prostate cancer (CRPC).
AR-V7 is primarily studied in prostate cancer, where it has established prognostic significance.
Prostate Cancer
Expression: AR-V7 is often overexpressed in castration-resistant prostate cancer (CRPC).
Prognosis: High levels of AR-V7 are associated with poor prognosis, treatment resistance, and shorter overall survival. It is also used as a biomarker to predict response to therapies like enzalutamide and abiraterone.
(Will delete Record if Target field = "Delete") Home